Abstract
Non-alcoholic fatty liver disease shares many features of metabolic syndrome and its presence could signify a substantial cardiovascular risk above and beyond that conferred by individual risk factors. This study is an attempt to investigate the association of non-alcoholic fatty liver disease with carotid intima-media thickness and plaque as surrogate measures of increased cardiovascular risk. The study was conducted on 645 non diabetic, non alcoholic subjects in the age range of 20–60 years. Metabolic syndrome was assessed by using ATP III and ADA (2005) criteria. Anthropometric factors—waist circumference and blood pressure were measured. Fasting serum samples were analyzed for glucose, triglyceride, cholesterol and its fractions, insulin, alanine and aspartate transaminases, gamma glutamyl transferase and free fatty acids. Insulin resistance and secretion were calculated by homeostasis model and insulin sensitivity by QUICKI index. Liver ultrasonographic scanning was used for assessing fatty liver. Carotid atherosclerosis was assessed by B-mode ultrasonography of common carotid artery and internal carotid artery. The prevalence of non-alcoholic fatty liver disease was 15.6 % in non alcoholic population and 68.5 % of non-alcoholic fatty liver disease had metabolic syndrome, which was associated with hyperinsulinemia, insulin resistance, insulin insensitivity along with elevated levels of waist circumference, blood pressure, triglyceride, FFA and decreased HDL cholesterol. NAFLD patients had markedly greater carotid intima media thickness than non NAFLD subjects with MCIMT of 591.6 ± 108 and 489.5 ± 132.4 μm (P < 0.001) and plaque prevalence of 19.2 and 2.2 %, respectively, thus the carotid intima media thickness is associated with NAFLD.
Similar content being viewed by others
References
Angulo P. Nonalcoholic fatty liver disease. N Engl J Med. 2002;346:1221–31.
Neuschwander Tetri BA, Caldwell SH. Nonalcoholic steatohepatitis: summary of an AASLD single topic conference. Hepatology. 2003;37:1202–19.
Sharma P, Mishra S, Ajmera P, Mathur S. Oxidative stress in metabolic syndrome. Indian J Clin Biochem. 2005;20(1):145–9.
Mishra S, Yadav D, Gupta M, Mishra H, Sharma P. Hyperinsulinemia predisposes to NAFLD. Indian J Clin Biochem. 2008;23(2):130–5.
Targher G, Marra F, Marchesini G. Increased risk of cardiovascular disease in nonalcoholic fatty liver disease: causal effect or epiphenomenon? Diabetologia. 2008;51(11):1947–53.
Raitakari OT, Juonala M, Kahonen M, Taittonen L, Laitinen T, Maki-Torkko N, et al. Cardiovascular risk factors in childhood and carotid artery intima-media thickness in adulthood: the Cardiovascular Risk in Young Finns Study. JAMA. 2003;290(17):2277–83.
Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486–97.
Alberti KGMM, Zimmet P, Shaw J, IDF Epidemiology Task Force Consensus Group. The metabolic syndrome: a new worldwide definition. Lancet. 2005;366:1059–62.
Trinder P. Enzymatic method of glucose estimation. J Clin Pathol. 1969;22:246.
Trinder P. Enzymatic method of triglyceride estimation. Ann Clin Biochem. 1969;6:24–7.
The Expert Panel Report of the National Cholesterol Education Programme, Expert Panel on Detection, Evaluation and Treatment of high blood cholesterol in adults. Arch Intern Med. 1988;148:36–69.
Myers GL, Cooper GR, Henderson LO, Hassemer DJ, Kimberly MM. Standardization of lipid and lipoprotein measurement. In: Rifai N, Warnick GR, Dominiczak MH, editors. Handbook of lipoprotein testing. Washington, DC: AACC Press; 2000. p. 717–48.
Bergmeyer HU, Scheibe P, Wahlefeld AW. Optimization of methods for aspartate aminotransferase and alanine aminotransferase. Clin Chem. 1978;24:1.
Saris NE. Revised IFCC method for aspartate aminotransferase. Clin Chem. 1978;24:720–1.
Shaw LM, Stromme JH, London JL, Theodorsen L. IFCC methods for the determination of enzymes part 4. IFCC method for gamma-glutamyl transferase [(gamma-glutamyl)-peptide; amino acid gamma-glutamyl transferase, EC 2.3.2.2.]. Clin Chem Acta. 1983;135:315F–38F.
Shimizu S, Inoue K, Tani Y, Yamada H. Enzymatic determination of serum-free fatty acids: a colorimetric method. Anal Biochem. 1979;98:341–5.
Andersen L, Dinesen B, Jørgensen PN, Poulsen F, Røder ME. Enzyme immunoassay for intact human insulin in serum or plasma. Clin Chem. 1993;38:578–82.
Matthews DR, Hosker JP, Rudenski AS. Homeostasis model assessment: insulin resistance and b-cell function from fasting plasma glucose and insulin concentration. Diabetologia. 1985;28:412–9.
Levy JC, Matthews DR, Herman MP. Correct homeostasis model assessment (HOMA) evaluation uses the computer program. Diabetes Care. 1998;21:2191–2.
Katz A, Nambi SS, Mather K, Baron AD, Follmann DA, Sullivan G, Quon MJ. Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab. 2000;85:2402–10.
Saverymuttu SH, Joseph AEA, Amxwell JD. Ultrasound scanning in the detection of hepatic fibrosis and steatosis. Br Med J. 1986;292:13–5.
Lim TK, Lim E, Dwivedi G, Kooner J, Senior R. Normal value of carotid intima-media thickness—a surrogate marker of atherosclerosis: quantitative assessment by B-mode carotid ultrasound. J Am Soc Echocardiogr. 2008;21(2):112–6.
Brunt EM. Nonalcoholic steatohepatitis. Semin Liver Dis. 2004;24:3–20.
Younossi Z, Diehl AM, Ong JP. Nonalcoholic fatty liver disease: an agenda for clinical research. Hepatology. 2002;35:746–52.
Bellentani S, Saccoccio G, Masutti F, Croce LS, Brandi G, Sasso F, et al. Prevalence of and risk factors for hepatic steatosis in Northern Italy. Ann Intern Med. 2000;132:112–7.
Donati G, Stagni B, Piscaglia F, Venturoli N, Morselli-Labate AM, Rasciti L, et al. Increased prevalence of fatty liver in arterial hypertensive patients with normal liver enzymes: role of insulin resistance. Gut. 2004;53:1020–3.
Diehl AM. Fatty liver, hypertension and the metabolic syndrome. Gut. 2004;53:923–4.
Assy N, Kaita K, Mymin D, Levy C, Rosser B, Minuk G. Fatty infiltration of liver in hyperlipidemic patients. Dig Dis Sci. 2000;45:1929–34.
Gupte P, Amarapurkar D, Agal S, Baijal R, Kulshrestha P, Pramanik S, et al. Non-alcoholic steatohepatitis in type 2 diabetes mellitus. J Gastroenterol Hepatol. 2004;19:854–8.
Alexander CM, Landsman PB, Teutch SM, Haffner SM. NCEP-defined metabolic syndrome, diabetes and prevalence of coronary heart disease among NHANES III participants aged 50 years and older. Diabetes. 2003;52:1210–4.
Cortez Pinto H, Camilo ME, Baptista A, De Oliveira AG, De Moura MC. Non-alcoholic fatty liver: another feature of the metabolic syndrome? Clin Nutr. 1999;18:353–8.
Angelico F, Del Ben M, Conti R, Francioso S, Feole K, Maccioni D, Antonini TM, Alessandri C. Non-alcoholic fatty liver syndrome: a hepatic consequence of common metabolic diseases. J Gastroenterol Hepatol. 2003;18:588–94.
Marchesini G, Bugianesi E, Forlani G, Cerelli F, Lenzi M, Manini R, Rizzetto M, Melchionda N. Nonalcoholic fatty liver, steatohepatitis and the metabolic syndrome. Hepatology. 2003;37:917–23.
del Sol IA, Bots ML, Grobbee DE, Hofman A, Witteman JC. Carotid intima-media thickness at different sites: relation to incident myocardial infarction. The Rotterdam study. Eur Heart J. 2002;23(12):934–40.
Kablak-Ziembicka A, Tracz W, Przewlocki T, Pieniazek P, Sokolowski A, Konieczynska M. Association of increased carotid intima-media thickness with the extent of coronary artery disease. Heart. 2004;90(11):1286–90.
Aygun C, Kocaman O, Sahin T, Uraz S, Hulagu S. Evaluation of METS frequency and carotid artery intima media thickness as risk factors for a atherosclerosis in patients with non-alcoholic fatty liver disease. Dig Dis Sci. 2008;53(5):1352–7.
Lewis GF, Carpentier A, Adeli K, Giacca A. Disordered fat storage and mobilization in the pathogenesis of insulin resistance and type 2 diabetes. Endocr Rev. 2002;23:201–29.
Unger RH. Minireview: weapons of lean body mass destruction: the role of ectopic lipids in the metabolic syndrome. Endocrinology. 2003;144:5159–65.
Volzke H, Robinson DM, Kleine V, Deutscher R, Hoffmann W, Ludemann J. Hepatic steatosis is associated with an increased risk of carotid atherosclerosis. World J Gastroenterol. 2005;11(12):1848–53.
Caserta CA, Pendino GM, Alicante S, Amante A, Amato F, Fiorillo M, et al. Body mass index, cardiovascular risk factors, and carotid intima-media thickness in a pediatric population in southern Italy. J Pediatr Gastroenterol Nutr. 2010;51(2):216–20.
Cotichini R, Zuin M, Rosmini F, Mele A, Marcucci F. Cardiovascular risk factors, nonalcoholic fatty liver disease, and carotid artery intima-media thickness in an adolescent population in southern Italy. Am J Epidemiol. 2010;171(11):1195–202.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Mishra, S., Yadav, D., Gupta, M. et al. A Study of Carotid Atherosclerosis in Patients with Non-alcoholic Fatty Liver Disease. Ind J Clin Biochem 28, 79–83 (2013). https://doi.org/10.1007/s12291-012-0286-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12291-012-0286-8